Skip to main content
Roland Chen, MD, Urology, Keene, NH

RolandNChenMDFACS

Urology Keene, NH

Minimally Invasive Surgery, Stone Disease

Physician

Dr. Chen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Chen's full profile

Already have an account?

  • Office

    580 Court Street
    Keene, NH 03431
    Phone+1 603-354-6570

Education & Training

  • Cleveland Clinic Foundation
    Cleveland Clinic FoundationResidency, Urology, 1990 - 1996
  • Lewis Katz School of Medicine at Temple University
    Lewis Katz School of Medicine at Temple UniversityClass of 1990

Certifications & Licensure

  • NH State Medical License
    NH State Medical License 2022 - 2026
  • NV State Medical License
    NV State Medical License 1999 - 2023
  • FL State Medical License
    FL State Medical License 1997 - 2002
  • OH State Medical License
    OH State Medical License 1993 - 2001
  • MD State Medical License
    MD State Medical License 1996 - 1998
  • American Board of Urology Urology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2012-2013
  • Fellow (FACS) American College of Surgeons

Publications & Presentations

PubMed

Press Mentions

  • Data Reinforcing Impact of Bristol Myers Squibb Cardiovascular Portfolio to Be Presented at American Heart Association Scientific Sessions 2022
    Data Reinforcing Impact of Bristol Myers Squibb Cardiovascular Portfolio to Be Presented at American Heart Association Scientific Sessions 2022November 2nd, 2022
  • Bristol Myers Squibb to Demonstrate the Strength of Its Growing Cardiovascular Portfolio at the American College of Cardiology’s 71st Annual Scientific Session
    Bristol Myers Squibb to Demonstrate the Strength of Its Growing Cardiovascular Portfolio at the American College of Cardiology’s 71st Annual Scientific SessionMarch 21st, 2022
  • Bristol Myers Squibb Announces Positive Topline Results from Phase 3 VALOR-HCM Trial, Evaluating Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy
    Bristol Myers Squibb Announces Positive Topline Results from Phase 3 VALOR-HCM Trial, Evaluating Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction TherapyFebruary 16th, 2022
  • Join now to see all

Professional Memberships